Breaking News

Evotec Acquires Cell Culture Service

January 3, 2013

Expands drug discovery services

Evotec AG has acquired Cell Culture Service GmbH (CCS), based in Hamburg, Germany, for $1.5 million in cash and an earn-out payment of $1.4 million in cash. CCS supplies custom cells and cell-based reagents such as recombinant assay cell lines, assay-ready Frozen Instant Cells, qualified membranes, and proteins for high throughput screening.
 
The acquisition expands Evotec's drug discovery and early development solutions for pharma and biotechnology companies. CCS' large-scale processes for cell production, freezing and storage, as well as the team of specialized cell culture scientists and technicians, will be fully integrated into Evotec's Hamburg operations.
 
"Through the acquisition of CCS, Evotec strengthens its cell culture capabilities and gains access to a growing base of customers using cell- based assays in their drug discovery processes. CCS' experience and technologies for large scale cell production are a perfect fit with Evotec's screening and in vitro pharmacology activities,” said Dr. Mario Polywka, chief operating officer of Evotec AG.
 
Dr. Oliver Wehmeier, chief executive officer of CCS, said, "We are excited to join forces with Evotec. Our portfolio of custom products perfectly complements Evotec's integrated service offering. In return, our customers, who have relied on CCS' products and services for many years, will gain access to Evotec's broad range of screening technologies, which add a tremendous value to the assay-ready cells and cell-based reagents we provide."

blog comments powered by Disqus
  • Cold Chain Packaging Trends

    Cold Chain Packaging Trends

    Kristin Brooks, Contract Pharma||February 4, 2016
    Susan Li of UPS discusses supply chain trends, challenges, and packaging innovations

  • Packaging Equipment Trends Preview

    Packaging Equipment Trends Preview

    Kristin Brooks, Contract Pharma||January 26, 2016
    Christian Treitel of Bosch Packaging Technology discusses trends and capabilities

  • Tackling Drug Serialization Challenges

    Tackling Drug Serialization Challenges

    Tim Wright, editor||January 22, 2016
    Siemens and Adents together will develop a combined hardware plus software solution for pharma industry

  • Elemental Impurity Testing

    Elemental Impurity Testing

    Dr. Andrew Fussell, PANalytical ||January 28, 2016
    Advances in elemental impurity testing aid compliance with new USP requirements

  • Fit-For-Purpose Assay Development in Bioanalysis

    Fit-For-Purpose Assay Development in Bioanalysis

    Franklin Spriggs, Ligand Binding Assay Group Leader; Ashley Brant, Program Manager, AIT Bioscience||January 28, 2016
    The success of bioanalytical studies relies on the selection of the most suitable analytical method but the timeline of method development and types of analyses involved vary greatly.

  • Optimizing Collaboration Effectiveness in Alliance Partnerships

    Optimizing Collaboration Effectiveness in Alliance Partnerships

    Mary Jo Lamberti, Phil Birch, Ranjana Chakravarthy, Ken Getz, Tufts CSDD||January 28, 2016